Avadel Pharmaceuticals Plc ADR (AVDL)

Feb 20, 2025, 4:05 PM EST - 2 days ago

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Feb 11, 2025, 6:08 PM EST - 11 days ago

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 10, 2025, 9:00 AM EST - 12 days ago

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

Jan 13, 2025, 12:56 PM EST - 5 weeks ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI

Jan 12, 2025, 3:26 AM EST - 5 weeks ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 8, 2025, 4:15 PM EST - 6 weeks ago

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Jan 3, 2025, 8:00 AM EST - 7 weeks ago

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Nov 13, 2024, 8:00 AM EST - 3 months ago

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 3:19 PM EST - 3 months ago

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:00 AM EDT - 4 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

Oct 17, 2024, 10:03 AM EDT - 4 months ago

US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 9:41 AM EDT - 4 months ago

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Sep 3, 2024, 8:30 AM EDT - 6 months ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 3, 2024, 8:00 AM EDT - 6 months ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

Aug 28, 2024, 8:00 AM EDT - 6 months ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Aug 9, 2024, 12:27 PM EDT - 7 months ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Jun 27, 2024, 4:05 PM EDT - 8 months ago

Avadel Pharmaceuticals to Join Russell 3000® Index

May 22, 2024, 8:00 AM EDT - 9 months ago

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

May 21, 2024, 7:00 AM EDT - 9 months ago

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

May 8, 2024, 7:00 AM EDT - 10 months ago

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 8:00 AM EDT - 10 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Apr 2, 2024, 3:40 AM EDT - 11 months ago

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 1, 2024, 8:00 AM EDT - 11 months ago

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Mar 4, 2024, 3:37 PM EST - 1 year ago

Avadel Pharmaceuticals Issues Statement On Patent Litigation

Mar 4, 2024, 10:43 AM EST - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 6:30 AM EST - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 28, 2024, 2:56 AM EST - 1 year ago

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Jan 11, 2024, 11:31 AM EST - 1 year ago

Avadel May Continue To Outperform With Positive Launch Momentum

Nov 14, 2023, 4:00 PM EST - 1 year ago

Avadel: Lumryz Lights Up The Oxybate Market, Maintaining Buy Rating

Nov 8, 2023, 1:48 PM EST - 1 year ago

Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:00 AM EST - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 20, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

Oct 5, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit

Aug 21, 2023, 11:20 PM EDT - 1 year ago

Avadel Pharmaceuticals: A Resilient Buy; A Comprehensive Assessment Of Potential Prospects

Aug 9, 2023, 2:02 PM EDT - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

Jul 20, 2023, 3:26 PM EDT - 1 year ago

Avadel Pharmaceuticals: Winning Is Sweet

Jun 22, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII

Jun 14, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation's 2023 Young Investigators Research Forum

Jun 13, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 31, 2023, 4:00 PM EDT - 1 year ago

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

May 17, 2023, 2:56 AM EDT - 1 year ago

Avadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain Bullish

May 3, 2023, 2:00 PM EDT - 1 year ago

Avadel Pharmaceuticals' Strategic Moves To Conquer The Narcolepsy Market (Rating Upgrade)

May 1, 2023, 1:20 PM EDT - 1 year ago

Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

Apr 19, 2023, 8:20 AM EDT - 2 years ago

Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

Mar 31, 2023, 9:25 PM EDT - 2 years ago

Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call Transcript